CNS Pharmaceuticals is pursuing 
a number of future targets in oncology.


Cancers metastatic to the brain pass through the bloodstream and enter the central nervous system through a breakdown of the blood-brain barrier.

Treatment of Metastases

Unfortunately this very mechanism by which common cancers enter the brain is the same mechanism that makes them nearly as difficult to treat as primary brain cancers such as glioblastoma.


As Berubicin appears to cross the blood-brain barrier in high concentrations, it has the potential to treat cancers that have metastasized to the brain.

Metastatic Breast Cancer

While breast cancer is the most common cancer in women, breast cancer brain metastasis is the second most common cause of brain metastasis, affecting around 25% of advanced breast cancer patients.1

Taxanes are frequently prescribed cytotoxic agents for patients with breast cancer, however, these agents are unable to cross the blood-brain barrier, limiting their efficacy for central nervous system malignancies.4 

Berubicin, which crosses the blood-brain barrier, may offer novel treatment of breast cancer brain metastases.

2.3 Million

An estimated 2.3 million new cases of breast cancer are diagnosed globally each year.2


6% of breast cancer patients present with metastatic breast cancer at diagnosis.3


  • 1. Stokes M, Berfeld N, Gayle A, et al. Medicine (Baltimore). 2022;101(26):e29783.
  • 2. Nawrocki S, Sugajska A. BMC Cancer. 2020;20(1):231.
  • 3. Sun H, Xu J, Dai S, Ma Y, Sun T. Cancer Med. 2022;10.1002/cam4.5021.
  • 4. (accessed August 2022).
  • 5. (accessed August 2022).
  • 6. Fitzgerald DP, Emerson DL, Qian Y, et al. Mol Cancer Ther. 2012;11(9):1959-1967.
  • 7. Lei L, Wang XJ, Tang SC. Crit Rev Oncol Hematol. 2022;176:103727.
  • 8. Bernatz S, Ilina EI, Devraj K, et al. J Exp Clin Cancer Res. 2019;38(1):434.